Search Results

Switch Therapeutics today announced that Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will present and host investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.

Switch Therapeutics today announced that Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics, will participate in a virtual fireside chat at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024 at 1:05 p.m. ET (10:05 a.m. PT).

Switch Therapeutics today announced the appointment of Charles Allerson, Ph.D.

Petros Pharmaceuticals, Inc. announces it has formed an Advisory Committee to provide guidance as the company prepares for the potential Rx-to-OTC switch for STENDRA for both development and communication with the U.S. Food and Drug Administration.

Medigene AG presented superior T cell receptor engineered T cell functionality upon combination of optimal affinity 3S TCRs with the PD1-41BB costimulatory switch protein at the 7th International Neoantigen Summit held in Amsterdam, Netherlands from April 29 - May 1, 2024.

Switch Therapeutics today announced that Dee Data, Ph.D., Co-Founder and CEO of Switch Therapeutics, will present a corporate overview at the Morgan Stanley 21st Annual Global Healthcare Conference.

Medigene AG presents superior recombinant T cell receptor engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein at the American Association for Cancer Research Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, USA.

Switch Therapeutics today announced the formation of its Scientific Advisory Board.

QurAlis Corporation today announced preclinical data that showed the company’s UNC13A splice-switching antisense oligonucleotides (ASOs) modulate UNC13A splicing and restore normal synaptic activities in ALS and FTD.